基蛋生物
(603387)
| 流通市值：42.91亿 | | | 总市值：42.91亿 |
| 流通股本：5.07亿 | | | 总股本：5.07亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 820,157,752.94 | 555,336,020.64 | 267,501,249.08 | 1,051,714,310.24 |
| 营业收入 | 820,157,752.94 | 555,336,020.64 | 267,501,249.08 | 1,051,714,310.24 |
| 二、营业总成本 | 628,168,087.45 | 410,667,258.04 | 192,223,993.5 | 797,401,359.97 |
| 营业成本 | 253,028,406.67 | 171,661,629.15 | 79,333,175.66 | 317,725,137.15 |
| 税金及附加 | 11,521,580.64 | 7,523,998.73 | 3,325,045.63 | 13,376,651.9 |
| 销售费用 | 170,798,128.14 | 106,658,831.42 | 48,704,689.71 | 231,075,291.94 |
| 管理费用 | 68,198,173.91 | 43,582,948.25 | 22,143,668.01 | 91,370,201.47 |
| 研发费用 | 126,905,279.8 | 82,796,101.64 | 41,352,138.53 | 157,404,097.24 |
| 财务费用 | -2,283,481.71 | -1,556,251.15 | -2,634,724.04 | -13,550,019.73 |
| 其中:利息费用 | 5,708,559.28 | 4,171,918.71 | 2,460,046.19 | 12,089,166.52 |
| 其中:利息收入 | 16,304,568.12 | 11,736,005.98 | 7,575,531.9 | 33,085,124.21 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 20,943,809.95 | 15,582,797.05 | 5,135,485.63 | 27,002,141.94 |
| 加:投资收益 | 52,238,323.54 | 51,917,978.64 | -643,155.49 | -8,710,147.94 |
| 资产处置收益 | 30,122.97 | 181,142.69 | 191,119.01 | -47,740.64 |
| 资产减值损失(新) | -15,407,636.87 | -11,331,288.36 | -1,463,175.42 | -28,682,414.8 |
| 信用减值损失(新) | -6,284,030.21 | -10,324,188.74 | -8,326,929.52 | -29,099,804.56 |
| 其他收益 | 15,991,582.35 | 15,238,785.26 | 11,031,470.75 | 16,244,938.72 |
| 四、营业利润 | 259,501,837.22 | 205,933,989.14 | 81,202,070.54 | 231,019,922.99 |
| 加:营业外收入 | 1,041,230.09 | 273,008.49 | 50 | 1,922,589.61 |
| 减:营业外支出 | 3,174,309.43 | 1,467,839.82 | 314,042.98 | 5,250,975.98 |
| 五、利润总额 | 257,368,757.88 | 204,739,157.81 | 80,888,077.56 | 227,691,536.62 |
| 减:所得税费用 | 26,564,564.94 | 21,001,274.96 | 7,647,818.71 | 15,771,136.96 |
| 六、净利润 | 230,804,192.94 | 183,737,882.85 | 73,240,258.85 | 211,920,399.66 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 230,804,192.94 | 183,737,882.85 | 73,240,258.85 | 211,920,399.66 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 232,406,080.16 | 184,291,348.06 | 76,303,243.95 | 220,661,381.93 |
| 少数股东损益 | -1,601,887.22 | -553,465.21 | -3,062,985.1 | -8,740,982.27 |
| 扣除非经常损益后的净利润 | 159,811,374.79 | 118,059,308.49 | 65,836,884.88 | 183,936,000.17 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.46 | 0.36 | 0.15 | 0.44 |
| (二)稀释每股收益 | 0.46 | 0.36 | 0.15 | 0.44 |
| 八、其他综合收益 | -655,269.45 | -515,290.71 | -239,372.51 | -325,162.65 |
| 归属于母公司股东的其他综合收益 | -655,269.45 | -515,290.71 | -239,372.51 | -325,162.65 |
| 九、综合收益总额 | 230,148,923.49 | 183,222,592.14 | 73,000,886.34 | 211,595,237.01 |
| 归属于母公司股东的综合收益总额 | 231,750,810.71 | 183,776,057.35 | 76,063,871.44 | 220,336,219.28 |
| 归属于少数股东的综合收益总额 | -1,601,887.22 | -553,465.21 | -3,062,985.1 | -8,740,982.27 |
| 公告日期 | 2026-10-28 | 2026-08-27 | 2026-04-30 | 2026-04-30 |
| 审计意见(境内) | | | | 带强调事项段的无保留意见 |